Skip to main content
    Z

    Zimmer Biomet Holdings Inc (ZBH)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $101.44
    -1.78 (-1.72%)

    Market Cap: $19.53B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zimmer Biomet Holdings Inc (ZBH) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Zimmer Biomet Holdings (ZBH) trades at 12.0x trailing earnings and 2.3x sales. Its P/E of 12.0x is below its 5-year median of 14.7x. Its forward P/E is 11.4x. The median P/E across 9 similar companies is 21.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 5.3% higher over the next year. Its free cash flow yield is 8.5%.

    MultipleValue
    P/E (trailing)12.0x
    Forward P/E11.4x
    Price to sales2.3x
    Price to book1.5x
    EV/EBITDA11.6x
    Price to FCF11.8x
    EV/FCF16.1x
    PEG2.2
    FCF yield8.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 22.6% below 15.5x, its P/S is 28.1% below 3.2x and its P/B is 28.6% below 2.1x.

    MultipleCurrent5-year median10-year median
    P/E12.0x14.7x15.5x
    P/S2.3x3.2x3.2x
    P/B1.5x1.8x2.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 11.0x in 2025 to 27.2x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$89.9211.0x2.2x1.4x
    2024$105.6313.2x2.8x1.7x
    2023$121.7016.1x3.4x2.0x
    2022$127.5018.5x3.9x2.2x
    2021$127.0417.2x3.9x2.1x
    2020$154.0927.2x5.2x2.6x
    2019$149.6819.0x3.9x2.5x
    2018$103.7213.6x2.7x1.9x
    2017$120.6715.0x3.1x2.1x
    2016$103.2013.0x2.7x2.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ZBH

    What is ZBH's forward P/E ratio?

    Zimmer Biomet Holdings has a forward P/E ratio of 11.4x.

    Is ZBH stock overvalued?

    GNG's valuation label for ZBH is Undervalued. Its P/E of 12.0x compares with a median of 21.9x across 9 similar companies.

    What is ZBH's price to sales ratio?

    Zimmer Biomet Holdings has a price to sales ratio of 2.3x.

    What is Zimmer Biomet Holdings's average P/E ratio over 5 years?

    Zimmer Biomet Holdings's median P/E over the last 5 years is 14.7x, from 60 month-end values through Oct 2026.

    What is ZBH's PEG ratio?

    Zimmer Biomet Holdings has a PEG ratio of 2.2.